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Objective: The Vascular Registry (VR) on carotid procedures collects long-term outcomes on carotid artery stenting
(CAS) and carotid endarterectomy (CEA) patients. The purpose of this report is to describe in-hospital and 30-day CAS
outcomes in patients with atherosclerotic carotid artery disease (CAD; atherosclerosis [ATH]) compared to recurrent
carotid stenosis (RES) and radiation-induced stenosis (RAD).
Methods: The VR collects provider-reported data on CAS using a Web-based data management system. For this report,
data were analyzed at the preprocedure, procedure, predischarge, and 30-day intervals.
Results: As of November 20, 2008, there were 4017 patients with CAS with discharge data, of which 72% were due to
ATH. A total of 2321 patients were available for 30-day outcomes analysis (1623 ATH, 529 restenosis, 119 radiation,
17 dissection, 3 trauma, and 30 other). Baseline demographics showed that ATH occurred in older patients (72-years-
old), had the greatest history of coronary artery disease (CAD; 62%), myocardial infarction (MI; 24%), valvular heart
disease (8%), arrhythmia (16%), congestive heart failure (CHF; 16%), diabetes mellitus (DM; 35%), and chronic
obstructive pulmonary disease (COPD; 20%). RES had a higher degree of baseline stenosis (87.0 vs 85.8 ATH; P .010),
were less likely to be symptomatic (35.5% vs 46.3% ATH; P< .001), but had a greater history of hypertension, peripheral
vascular disease (PVD), and smoking. RAD was seen in younger patients (66.6 vs 71.7 ATH; P< .001), were more likely
to be male (78.2% vs 60.9% ATH; P < .001), and had less comorbidities overall, with the exception of amaurosis fugax,
smoking, and cancer. The only statistically significant difference in perioperative rates was in transient ischemic attack
(TIA; 2.7% ATH vs 0.9% RES; P  .02). There were no statistically significant differences in in-hospital death/
stroke/MI (ATH 5.4%, RES 3.8%, RAD 4.2%) or at 30 days (ATH 7.1%, RES 5.1%, RAD 5.0%). Even after adjusting for
age, gender, symptomatology, CHF, and renal failure, the only statistically significant difference at 30 days was amaurosis
fugax between ATH and RAD (odds ratio [OR] 0.13; P  .01).
Conclusion: Although patients with ATH have statistically significant comorbidities, they did not have statistically significant
increased rates of death/stroke/MI during hospitalization or within 30 days after discharge when compared to RES or RAD.
The CAS event rates for ATH vs RES and RAD are similar, despite prior published reports. Symptomatic ATH have
statistically significant higher rates of death/stroke/MI compared to asymptomatic cohort. Finally, consistent and accurate
entry of long-term data beyond initial hospitalization is essential to fully assess CAS outcomes since a significant number of
adverse events occur in the interval from hospital discharge to 30 days. (J Vasc Surg 2010;51:1116-23.)In the United States, stroke is the leading cause of serious
long-term disability and the third leading cause of death.1 Stroke
is the most devastating complication of carotid artery stenosis,
andatherosclerosis (ATH) is the leadingetiologyofcarotidartery
disease. Other etiologies include recurrent carotid stenosis (reste-
nosis [RES]) and radiation-induced (RAD) or accelerated ca-
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1116rotid ATH, which are considered high-risk factors for carotid
endarterectomy (CEA).
It has been reported that recurrent carotid stenosis (or
restenosis) occurs in approximately 20% of patients having
an interventional carotid procedure (prior carotid artery
stenting [CAS] or CEA), mostly asymptomatic.2,3 Given
the reported high event rates for carotid revascularization
with redo CEA, CAS is frequently the preferred alternative
to operative management in these patients.4
Radiation-induced or accelerated stenosis is a well-
defined entity and can occur up to 20 years after treat-
ment.5 Because stenotic lesions in this cohort are reported
to be multiple, long, surgically less accessible, consisting
primarily of fibrotic tissue, and at high risk for cranial nerve
palsy, CAS is felt by many to be the preferred intervention
compared to CEA.4,6
In 2008, the Society for Vascular Surgery (SVS) issued
clinical practice guidelines suggesting CAS for the treat-
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rotid stenosis (50%) and high perioperative risk, which
includes recurrent stenosis or radiation therapy to the
neck.7
As part of the rapid evolution in vascular interventional
techniques, there is a need for methods to assess efficacy of
CAS and compare these results in routine clinical practice
to conventional surgical procedures. Continued improve-
ment in surgical interventions and the rapid development
of CAS interventional devices and methods makes ongoing
comparison of CEA and CAS imperative to ensure quality
improvement.
In response to this need, the Vascular Registry (VR) on
carotid procedures was developed to collect long-term
outcomes on patients with CAS and CEA.8 As the first
societal registry to enroll patients with CAS and CEA, the
VR is the largest published database of CAS procedures in
the United States. As the most representative sample of
carotid artery procedures in the United States, the VR is a
wealth of information for studying the indications for CAS.
Whereas much is known about CAS procedures for the
primary indication of ATH, less is known about the total
experience with stenting including, for example, radiation-
induced stenosis.
The purpose of this report is to describe in-hospital
(procedural and predischarge) and 30-day outcomes in
patients treated with CAS comparing atherosclerotic CAD
(ATH) with nonatherosclerotic CAD (mainly restenosis
[RES] and radiation-induced stenosis [RAD]).
METHODS
VR data are reported by providers through Web-based
electronic data capture. The measurement schedule in-
cludes baseline (preoperative) information such as demo-
graphics, medical history, carotid symptom status, prepro-
cedural diagnostic imaging and laboratory, procedural
information including clinical utility, procedural and pre-
discharge complications; and follow-up information such as
postprocedure mortality, stroke, myocardial infarction
(MI), and other morbidity. All data entered into the VR are
fully compliant with the Health Insurance Portability and
Accountability Act (HIPAA) regulations and are auditable.
All data reports and analyses performed include only dein-
dentified and aggregated data.
The New England Research Institutes, Inc (NERI,
Watertown, Mass) maintains the online database. Funding
for the administration and database management of the VR
has been provided by the Society of Vascular Surgery (SVS,
Chicago, Ill).
Outcomes. The primary outcome measures are com-
bined death, stroke, and MI. Stroke is defined as any
nonconvulsive, focal neurologic deficit of abrupt onset
persisting more than 24 hours. The ischemic event must
correspond to a vascular territory. An MI is classified as
either Q wave MI in which one of the following criteria is
required: (1) chest pain or other acute symptoms consistent
with myocardial ischemia and new pathologic Q waves in
two or more contiguous electrocardiogram (ECG) leads;or (2) new pathologic Q waves in two or more contiguous
ECG leads and elevation of cardiac enzymes; or non-Q
wave MI, which is defined as CK ratio2 and CK-MB1
in the absence of new, pathologic Q waves. In addition,
although not considered specific outcomes but of interest,
transient ischemic attack (TIA) and amaurosis fugax (or
transient monocular blindness [TMB]) are also reported.
Analysis of the 30-day outcomes were based on only those
patients who had at least a 30-day follow-up visit (15
days) or experienced an endpoint (death, stroke, or MI)
within 30 days of treatment.
Procedural success data were also collected. A CAS
procedure is deemed successful when all of its components
are completed without the need of conversion to CEA, or
its abandonment before completion, and 30% residual
stenosis is achieved postprocedure.
Statistical methods. Tests of statistical significance
were conducted with 2 or Fisher’s exact tests for categoric
variables and analysis of variance (ANOVA) for continuous
variables. Descriptive statistics are listed as mean  SD for
continuous variables and percent (frequency) for categoric
variables. Subset analyses were performed using the two-
tailed t test for continuous variables and the 2 or Fisher’s
exact test, as necessary, for discrete/categoric data. Unad-
justed and adjusted odds ratios were used to compare the
primary outcomes across treatment groups. Odds ratios
were adjusted for age and any significant baseline factors
that were kept after using backward elimination methods.
Differences were considered significant if P  .05. All
statistical analyses were performed by NERI using SAS
Statistical Software (Cary, NC).
RESULTS
For the purpose of this report, data collected in the VR
from the beginning of electronic data entry on July 11,
2005, to November 20, 2008, were analyzed. There were
4017 patients with CAS with procedural and discharge
data, of which 72% underwent CAS for ATH. At 30 days,
there were 2321 patients with CAS in-hospital and 30-day
outcome data available for analysis (1623 ATH, 529 reste-
nosis, 119 radiation, 17 dissection, 3 trauma, and 30
CAS N=2,321
1,623
3
30
17
119
529 Atherosclerosis
Restenosis
Radiation
Dissection
Trauma
Other*
Fig 1. Carotid artery disease etiology for all carotid artery stent-
ing (CAS) patients. *Other includes aneurysm, pseudoaneurysm,
fibromuscular dysplasia, multiple and unknown etiologies.other), as illustrated in Fig 1. For purposes of this report,
us var
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ation (RAD).
Baseline demographics, seen in Table I, showed that
patients with ATH were the oldest (71.7-years-old), had
the greatest history of CAD (62.1%), MI (23.8%), valvular
heart disease (7.9%), cardiac arrhythmia (15.7%), conges-
tive heart failure (CHF; 16.1%), diabetes mellitus (DM;
34.6%), chronic obstructive pulmonary disease (COPD;
19.9%), and were the most likely to have a NYHA Class2
(13.5%). Recurrent stenosis patients had a higher degree of
baseline stenosis than patients with ATH (87.0 vs 85.8;
P  .010), were less likely to be symptomatic (35.5% vs
46.3%; P  .001), but had a greater history of hyperten-
sion, peripheral vascular disease (PVD), and smoking.
Radiation-induced patients were younger than patients
Table I. Baseline demographics, medical history, and eval
stenting (CAS) by disease etiology
ATH (n  1623)
n (%)
Demographics
Age (years) 71.7  10.01
Gender (male, %) 989 (60.9%)
Race (white, %) 1496 (92.2%)
Ethnicity (Hispanic, %) 92 (5.7%)
Medical history
CAD 1008 (62.1%)
MI 386 (23.8%)
VHD 128 (7.9%)
CA 255 (15.7%)
CHF 262 (16.1%)
HTN 1331 (82.0%)
DM 562 (34.6%)
Stroke 404 (24.9%)
TIA 373 (23.0%)
Amaurosis fugax 107 (6.6%)
COPD 323 (19.9%)
CRF 57 (3.5%)
PVD 586 (36.1%)
GI ulcer/bleeding 70 (4.3%)
Current or past smoker 914 (56.3%)
Cancer 248 (15.3%)
Coagulopathy 13 (0.8%)
ASA grade 3 122 (7.5%)
NYHA 2 219 (13.5%)
Carotid evaluation
Symptomatic 752 (46.3%)
Baseline stenosis (%) 85.8  9.12
Stenosis 80% 1016 (63.1%)
Baseline ultrasound 80% stenosis 1080 (66.5%)
Contralateral stenosis 405 (25.0%)
Stents deployed 1.1  0.33
Embolic protection 1549 (95.4%)
Stent type
Open 1080 (79.4%)
Closed 280 (20.6%)
Anti-platelet use 1588 (97.8%)
ATH, Atherosclerosis; RES, restenosis; RAD, radiation-induced; CAD, cor
cardiac arrhythmia; CHF, congestive heart failure; HTN, hypertension; DM
pulmonary disease; CRF, chronic renal failure; PVD, peripheral vascular dise
York Heart Association.
P values are based on 2 tests for categoric variables and t tests for continuowith ATH (66.6 vs 71.7; P  .001), were more likely tobe male (78.2% vs 60.9%; P  .001), and had less
comorbidities overall, with the exception of amaurosis
fugax, smoking, and cancer.
In-hospital outcomes. The only statistically signifi-
cant difference in in-hospital (includes procedure and pre-
discharge on initial hospitalization) adverse event rates
comparing ATH to RES or RAD was in TIA (2.7% ATH vs
0.9% RES; P  .02; Table II, A). When comparing both
disease etiology and presentation (eg, symptomatology), as
expected, there were some statistically significant differ-
ences, with symptomatic patients having higher in-hospital
event rates in general, compared with asymptomatic pa-
tients (Table II, B). In the ATH cohort, symptomatic
patients had a higher combined death/stroke/MI rate
(7.2% vs 3.8% asymptomatic [ASYMP]; P  .003) and a
n of carotid stenosis of patients with carotid artery
(n  529)
(%)
RAD (n  119)
n (%)
P value
ATH-RES
P value
ATH-RAD
 8.68 66.6  10.02 .24 .001
(52.4%) 93 (78.2%) .001 .001
(96.6%) 111 (93.3%) .001 .66
(1.9%) 3 (2.5%) .001 .21
(58.6%) 33 (27.7%) .15 .001
(23.1%) 15 (12.6%) .77 .005
(4.0%) 1 (0.8%) .002 .002
(8.5%) 13 (10.9%) .001 .19
(9.3%) 1 (0.8%) .001 .001
(84.3%) 84 (70.6%) .23 .002
(29.1%) 23 (19.3%) .02 .001
(25.3%) 24 (20.2%) .84 .25
(24.2%) 28 (23.5%) .57 .89
(9.1%) 19 (16.0%) .07 .001
(15.5%) 19 (16.0%) .02 .30
(2.6%) 0 (0.0%) .40 .03
(43.3%) 27 (22.7%) .003 .003
(5.9%) 5 (4.2%) .16 .999
(64.5%) 82 (68.9%) .001 .007
(11.2%) 110 (92.4%) .02 .001
(1.3%) 3 (2.5%) .30 .09
(6.4%) 8 (6.7%) .44 .86
(8.1%) 10 (8.4%) .001 .12
(35.5%) 60 (50.4%) .001 .39
 8.85 83.2  13.35 .010 .03
(68.4%) 67 (56.3%) .03 .14
(75.4%) 84 (70.6%) .001 .37
(24.8%) 29 (24.4%) .95 .999
 0.27 1.2  0.42 .07 .02
(96.8%) 106 (89.1%) .18 .002
(75.9%) 62 (78.5%) .12 .84
(24.1%) 17 (21.5%)
(98.3%) 111 (93.3%) .60 .007
artery disease; MI, myocardial infarction; VHD, valvular heart disease; CA,
betes mellitus; TIA, transient ischemic attack; COPD, chronic obstructive
I, gastrointestinal; ASA, American Society of Anesthesiology; NYHA, New
iables.uatio
RES
n
71.1
277
511
10
310
122
21
45
49
446
154
134
128
48
82
14
229
31
341
59
7
34
43
188
87.0
360
399
131
1.1
512
321
102
520
onary
, dia
ase; Ghigher stroke rate (5.5% vs 3.0% ASYMP; P  .02). In the
induc
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higher in-hospital rate of stroke (4.8% vs 1.5% ASYMP; P
.04) and TIA (2.7% vs 0% ASYMP; P  .005). The differ-
ences between symptomatology in in-hospital event rates in
the radiation-induced cohort did not reach statistical sig-
nificance, however, the numbers were small. When com-
paring in-hospital outcomes of symptomatic patients re-
Table II. A, In-hospital (intraprocedural and predischarge
disease etiology
Peri-op AEs
ATH (n  1623)
n (%)
RES (n  5
n (%)
Death/stroke/MI 87 (5.4%) 20 (3.8%
Death/stroke 74 (4.6%) 18 (3.4%
Mortality 14 (0.9%) 6 (1.1%
Stroke 67 (4.1%) 14 (2.6%
MI 20 (1.2%) 3 (0.6%
TIA 44 (2.7%) 5 (0.9%
Amaurosis fugax 5 (0.3%) 1 (0.2%
ATH, Atherosclerosis; RES, restenosis; RAD, radiation-induced; AE, adver
P values are based on Fisher’s exact test.
Events are defined as any AE occurring intraprocedural or predischarge.
Event rates are reported per-patient.
Table II. B, In-hospital (intraprocedural and predischarge
disease etiology and symptomatology
Peri-op AEs
ATH
SYMPT
(n  752)
n (%)
ASYMP
(n  871)
n (%) P value
SY
(n
n
Death/stroke/MI 54 (7.2%) 33 (3.8%) .003 10
Death/stroke 43 (5.7%) 31 (3.6%) .04 9
Mortality 7 (0.9%) 7 (0.8%) .79 1
Stroke 41 (5.5%) 26 (3.0%) .02 9
MI 12 (1.6%) 8 (0.9%) .26 1
TIA 23 (3.1%) 21 (2.4%) .45 5
Amaurosis fugax 1 (0.1%) 4 (0.5%) .38 1
ATH,Atherosclerosis;RES, restenosis;RAD, radiation-induced;AE, advers
TIA, transient ischemic attack.
P values were based on Fisher’s exact tests.
Table III. A, In-hospital (intraprocedural and predischarg
stenting (CAS) by disease etiology
Peri-op AEs
ATH (n  752)
n (%)
RES (n  1
n (%)
Death/stroke/MI 54 (7.2%) 10 (5.3%
Death/stroke 43 (5.7%) 9 (4.8%
Mortality 7 (0.9%) 1 (0.5%
Stroke 41 (5.5%) 9 (4.8%
MI 12 (1.6%) 1 (0.5%
TIA 23 (3.1%) 5 (2.7%
Amaurosis fugax 1 (0.1%) 1 (0.5%
AE, Adverse event; ATH, atherosclerosis; RES, restenosis; RAD, radiation-ceiving CAS by disease etiology (Table III, A), there wereno statistically significant differences. However, it is inter-
esting to note that patients with ATH had higher rates of
MI and TIA, and patients with RAD had high rates of
mortality, stroke, and amaurosis fugax. In asymptomatic
patients (Table III, B), patients with ATH had a statistically
significant higher in-hospital rate of TIA compared with
patients with RES (2.4% vs 0%; P  .001). Of note,
tcomes of carotid artery stenting (CAS) patients by
RAD (n  119)
n (%)
P value
ATH-RES
P value
ATH-RAD
5 (4.2%) .17 .83
5 (4.2%) .32 .999
1 (0.8%) .60 .999
5 (4.2%) .15 .999
0 (0.0%) .23 .39
1 (0.8%) .02 .36
2 (1.7%) .999 .08
nt; MI, myocardial infarction; TIA, transient ischemic attack.
tcomes of patients with carotid artery stenting (CAS) by
RES RAD
)
ASYMP
(n  341)
n (%) P value
SYMPT
(n  60)
n (%)
ASYMP
(n  59)
n (%) P value
) 10 (2.9%) .23 4 (6.7%) 1 (1.7%) .36
) 9 (2.6%) .21 4 (6.7%) 1 (1.7%) .36
) 5 (1.5%) .43 1 (1.7%) 0 (0.0%) .999
) 5 (1.5%) .04 4 (6.7%) 1 (1.7%) .36
) 2 (0.6%) .999 0 (0.0%) 0 (0.0%) .36
) 0 (0.0%) .005 0 (0.0%) 1 (1.7%) .50
) 0 (0.0%) .36 1 (1.7%) 1 (1.7%) .999
t; SYMPT, symptomatic;ASYMP, asymptomatic;MI,myocardial infarction;
utcomes of symptomatic patients with carotid artery
Symptomatic
RAD (n  60)
n (%)
P value
ATH-RES
P value
ATH-RAD
4 (6.7%) .42 .999
4 (6.7%) .72 .77
1 (1.7%) .999 .46
4 (6.7%) .86 .57
0 (0.0%) .48 .999
0 (0.0%) .999 .40
1 (1.7%) .36 .14
ed; MI, myocardial infarction; TIA, transient ischemic attack.) ou
29)
)
)
)
)
)
)
)
se eve) ou
MPT
 188
(%)
(5.3%
(4.8%
(0.5%
(4.8%
(0.5%
(2.7%
(0.5%
e evene) o
88)
)
)
)
)
)
)
)although not statistically significant, the asymptomatic RES
induc
er disc
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RAD).
Thirty-day outcomes. There were no statistically sig-
nificant differences in 30-day (includes in-hospital through
30 days) adverse event rates between ATH and RES or
RAD in the primary outcome of combined stroke/
death/or MI, or the individual outcomes of death, stroke,
MI, TIA, or amaurosis fugax (or TMB; Table IV, A).
When comparing both disease etiology and presenta-
Table III. B, In-hospital (intraprocedural and predischarg
stenting (CAS) by disease etiology
Peri-op AEs
ATH (n  871)
n (%)
RES (n  3
n (%)
Death/stroke/MI 33 (3.8%) 10 (2.9%
Death/stroke 31 (3.6%) 9 (2.6%
Mortality 7 (0.8%) 5 (1.5%
Stroke 26 (3.0%) 5 (1.5%
MI 8 (0.9%) 2 (0.6%
TIA 21 (2.4%) 0 (0.0%
Amaurosis fugax 4 (0.5%) 0 (0.0%
AE, Adverse event; ATH, atherosclerosis; RES, restenosis; RAD, radiation-
Table IV. A, Thirty-day outcomes of patients with carotid
30-day AEs
ATH (n  1623)
n (%)
RES (n  52
n (%)
Death/stroke/MI 116 (7.1%) 27 (5.1%)
Death/stroke 98 (6.0%) 24 (4.5%)
Mortality 23 (1.4%) 9 (1.7%)
Stroke 82 (5.1%) 17 (3.2%)
MI 25 (1.5%) 4 (0.8%)
TIA 52 (3.2%) 9 (1.7%)
Amaurosis fugax 6 (0.4%) 1 (0.2%)
AE, Adverse event; ATH, atherosclerosis; RES, restenosis; RAD, radiation-
P values are based on Fisher’s exact test.
Events are defined as any AE occurring intraprocedure, predischarge, or aft
Event rates are reported per-patient.
Table IV. B, Thirty-day outcomes of patients with carotid
symptomatology
30-day AEs
ATH
SYMPT
(n  752)
n (%)
ASYMP
(n  871)
n (%) P value
SY
(n
n
Death/stroke/MI 67 (8.9%) 49 (5.6%) .01 12
Death/stroke 54 (7.2%) 44 (5.1%) .08 11
Mortality 10 (1.3%) 13 (1.5%) .84 1
Stroke 49 (6.5%) 33 (3.8%) .02 11
MI 14 (1.9%) 11 (1.3%) .42 1
TIA 28 (3.7%) 24 (2.8%) .32 8
Amaurosis fugax 1 (0.1%) 5 (0.6%) .23 1
ATH,Atherosclerosis;RES, restenosis;RAD, radiation-induced;AE, advers
TIA, transient ischemic attack.
P values were based on Fisher’s exact tests.tion (eg, symptomatology), as expected there were somestatistically significant differences, with symptomatic pa-
tients, in general, having higher 30-day event rates com-
pared with asymptomatic patients (Table IV,B). Of note, in
the ATH cohort, symptomatic patients had a higher com-
bined death/stroke/MI rate (8.9% vs 5.6% ASYMP; P 
.01) and a higher stroke rate (6.5% vs 3.8% ASYMP; P 
.02), which was similar to what was observed periopera-
tively. In the recurrent stenosis cohort (RES), symptomatic
patients had a higher 30-day rate of stroke (5.9% vs 1.8%
utcomes of asymptomatic patients with carotid artery
Asymptomatic
RAD (n  59)
n (%)
P value
ATH-RES
P value
ATH-RAD
1 (1.7%) .60 .72
1 (1.7%) .48 .72
0 (0.0%) .33 .999
1 (1.7%) .16 .999
0 (0.0%) .73 .999
1 (1.7%) .001 .999
1 (1.7%) .58 .28
ed; MI, myocardial infarction; TIA, transient ischemic attack.
ry stenting (CAS) by disease etiology
RAD (n  119)
n (%)
P value
ATH vs RES
P value
ATH vs RAD
6 (5.0%) .11 .46
6 (5.0%) .23 .84
2 (1.7%) .68 .69
5 (4.2%) .09 .83
0 (0.0%) .20 .41
1 (0.8%) .07 .26
2 (1.7%) .999 .10
ed; MI, myocardial infarction; TIA, transient ischemic attack.
harge to 30 days.
ry stenting (CAS) by disease etiology and
RES RAD
)
ASYMP
(n  341)
n (%) P value
SYMPT
(n  60)
n (%)
ASYMP
(n  59)
n (%) P value
) 15 (4.4%) .41 4 (6.7%) 2 (3.4%) .68
) 13 (3.8%) .28 4 (6.7%) 2 (3.4%) .68
) 8 (2.3%) .17 1 (1.7%) 1 (1.7%) .999
) 6 (1.8%) .02 4 (6.7%) 1 (1.7%) .36
) 3 (0.9%) .999 0 (0.0%) 0 (0.0%) .36
) 1 (0.3%) .001 0 (0.0%) 1 (1.7%) .50
) 0 (0.0%) .36 1 (1.7%) 1 (1.7%) .999
t; SYMPT, symptomatic;ASYMP, asymptomatic;MI,myocardial infarction;e) o
41)
)
)
)
)
)
)
)arte
9)
inducarte
MPT
 188
(%)
(6.4%
(5.9%
(0.5%
(5.9%
(0.5%
(4.3%
(0.5%
e evenASYMP; P  .02) and TIA (4.3% vs 0.3% ASYMP; P 
induc
induc
al; MI
hronic
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hospital rates. There were no statistically significant differ-
ences between symptomatology in 30-day event rates in the
radiation-induced cohort.
When comparing 30-day outcomes of symptomatic pa-
tients receiving CAS by disease etiology (Table V, A), there
were no statistically significant differences, which is similar to
what was observed in-hospital. However, it is interesting to
note that patients with ATH had higher combined event rates
(death, stroke, MI) and high rates of MI, and patients with
RAD had high rates of mortality, stroke, and amaurosis fugax.
Table V. A, Thirty-day outcomes of symptomatic patient
30-day AEs
ATH (n  752)
n (%)
RES (n  1
n (%)
Death/stroke/MI 67 (8.9%) 12 (6.4%
Death/stroke 54 (7.2%) 11 (5.9%
Mortality 10 (1.3%) 1 (0.5%
Stroke 49 (6.5%) 11 (5.9%
MI 14 (1.9%) 1 (0.5%
TIA 28 (3.7%) 8 (4.3%
Amaurosis fugax 1 (0.1%) 1 (0.5%
AE, Adverse event; ATH, atherosclerosis; RES, restenosis; RAD, radiation-
Table V. B, Thirty-day outcomes of asymptomatic patien
30-day AEs
ATH (n  871)
n (%)
RES (n  3
n (%)
Death/stroke/MI 49 (5.6%) 15 (4.4%
Death/stroke 44 (5.1%) 13 (3.8%
Mortality 13 (1.5%) 8 (2.3%
Stroke 33 (3.8%) 6 (1.8%
MI 11 (1.3%) 3 (0.9%
TIA 24 (2.8%) 1 (0.3%
Amaurosis fugax 5 (0.6%) 0 (0.0%
AE, Adverse event; ATH, atherosclerosis; RES, restenosis; RAD, radiation-
Table VI. Risk-adjusted 30-day outcomes of patients with
Unadjusted
ATH vs RES ATH v
OR
(P value) 95% CI
OR
(P value)
Death/stroke/MI 1.43 (0.55) 0.93-2.20 1.45 (0.66)
Death/stroke 1.35 (0.49) 0.86-2.14 1.21 (0.93)
Mortality 0.83 (0.84) 0.38-1.81 0.84 (0.91)
Stroke 1.60 (0.27) 0.94-2.73 1.21 (0.93)
MI 2.05 (0.96) 0.71-5.93 N/A
TIA 1.91 (0.96) 0.94-3.91 3.91 (0.31)
Amaurosis fugax 1.96 (0.18) 0.24-16.31 0.22 (0.04)
ATH,Atherosclerosis;RES, restenosis;OR, odds ratio; CI, confidence interv
1Adjusted for age, gender, symptomatology, congestive heart failure, and cIn asymptomatic patients (Table V, B), patients with ATHhad a statistically significant higher 30-day rate of TIA com-
pared with patients with RES (2.8% vs 0.3%; P .005).
Even after adjusting for age, gender, symptomatology,
CHF, and chronic renal failure (Table VI), the only statis-
tically significant difference at 30 days was in amaurosis
fugax between ATH and radiation cohorts (odds ratio
[OR] 0.13; P  .01).
It is important to note that although there were few
statistically significant differences for combined events be-
tween the cohorts, 25% of atherosclerotic events and 24% of
the nonatherosclerotic events occurred after the in-hospital
carotid artery stenting (CAS) by disease etiology
Symptomatic
RAD (n  60)
n (%)
P value
ATH-RES
P value
ATH-RAD
4 (6.7%) .31 .81
4 (6.7%) .63 .999
1 (1.7%) .70 .57
4 (6.7%) .87 .999
0 (0.0%) .33 .62
0 (0.0%) .68 .26
1 (1.7%) .36 .14
ed; MI, myocardial infarction; TIA, transient ischemic attack.
th carotid artery stenting (CAS) by disease etiology
Asymptomatic
RAD (n  59)
n (%)
P value
ATH-RES
P value
ATH-RAD
2 (3.4%) .48 .77
2 (3.4%) .45 .76
1 (1.7%) .33 .60
1 (1.7%) .10 .72
0 (0.0%) .77 .999
1 (1.7%) .005 .999
1 (1.7%) .33 .33
ed; MI, myocardial infarction; TIA, transient ischemic attack.
tid artery stenting (CAS) by disease etiology
Adjusted1
ATH vs RES ATH vs RAD
% CI
OR
(P value) 95% CI
OR
(P value) 95% CI
-3.37 1.31 (0.47) 0.85-2.03 1.12 (0.96) 0.47-2.63
-2.82 1.25 (0.43) 0.79-1.99 0.96 (0.74) 0.41-2.28
-3.61 0.78 (0.84) 0.35-1.71 0.49 (0.44) 0.11-2.20
-3.05 1.46 (0.29) 0.85-2.50 1.03 (0.75) 0.40-2.64
/A 1.92 (0.96) 0.66-5.58 N/A N/A
-28.50 1.84 (0.97) 0.89-3.77 3.23 (0.40) 0.44-23.87
-1.09 1.90 (0.13) 0.22-16.00 0.13 (0.01) 0.02-0.72
,myocardial infarction; N/A, not applicable; TIA, transient ischemic attack.
renal failure.s with
88)
)
)
)
)
)
)
)ts wi
41)
)
)
)
)
)
)
)caro
s RAD
95
0.62
0.52
0.20
0.48
N
0.54
0.04period, as illustrated in Fig 2. Approximately 40% of the
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deaths occurred after the in-hospital period, which stresses
the importance of patient follow-up.
Secondary outcomes. Secondary outcomes are shown
by etiology in Table VII. Patients with restenosis had
shorter hospital stays on average (1.6 days) than patients
with ATH (2.2 days; P  .001) and were less likely to
experience hypotension requiring treatment (1.3% vs 4.7%
ATH; P  .001). Patients who received radiation were
more likely to experience puncture site complications (2.5%
vs 0.2% ATH; P  .009).
DISCUSSION
The introduction of CAS to clinical practice has
changed the selection criterion of patients with extracranial
CAD for surgical intervention. Although there was early
enthusiasm that CAS would be favorable for all patients,
recent reports are mixed regarding the utility of CAS for
asymptomatic patients and for patients with symptomatic
lesions with good surgical anatomy.8,9 In response to the
favorable results of CAS from ARCHER and SAPPHIRE
for patients who are at high surgical risk or who have
unfavorable anatomy for surgery, the Center for Medicare
and Medicaid Services (CMS) has offered payment for
these patients but has waited for additional data to support
broader application.10,11 Thereafter, randomized con-
trolled trials such as SPACE and EVA-3S demonstrated less
favorable results.12,13
In response to the need to provide ongoing assessment for
the performance of new devices and techniques compared to
conventional surgical options, the VR was developed to pro-
vide longitudinal data entry. This not only addresses the
science needed to answer critical clinical questions but also
addresses means to provide quality assurance and fulfill recer-
tification requirements of federal agencies.
In this registry, although patients with ATH appear to
be sicker due to statistically significant comorbidities, they
did not have statistically significant increased rates of
Fig 2. Comparison of perioperative and 30-day event rates.death/stroke/MI in-hospital or 30 days after dischargewhen compared to other etiologies. Although the VR
30-day results of death/stroke in ATH vs RES are not
statistically significant (6% ATH vs 4.5% RES; P  .84),
AbuRahma et al14 reported a statistically significant in-
crease in 30-day rates of death/stroke in patients undergo-
ing primary CAS compared with those undergoing CAS for
post-CEA restenosis (7.4% primary CAS vs 0.9% restenosis;
P .03).14 However, Cuadra et al15 reported lower 30-day
rates of death/stroke in ATH compared to RES (3.0%
ATH vs 5.1% RES; P .51).15 With continued enrollment
and follow-up, analysis of VR will supplement randomized
trials by providing CAS outcomes in current clinical prac-
tice with sufficient numbers to serve as an outcome assess-
ment tool of important patient subsets.
The current report compares the short-term efficacy of
carotid stents in the management of atherosclerotic, recur-
rent, and radiation-induced carotid lesions.
In a prior report, the VR demonstrated that CEA had
better 30-day event rates than CAS, with the 30-day data
being valuable in making this determination, as there was a
demonstrated increase in event rates from the in-hospital to
30-day interval.8 A similar increase was noted in this analysis,
with the increase in ATH being greater than in the patients
with restenosis. An important conclusion of this analysis is the
need for a 30-day reporting interval, as the in-hospital event
rate in both groups did not reflect the 30-day results.
It is also noteworthy that given the current CMS re-
porting requirement, only 87 death/stroke/MI events in a
little less than 4017 discharges or just over 2.2% events
would be reported, compared to 30-day data. One could
contend that 30-day event rates with less than 100% follow-up
may underestimate, overestimate, or correctly estimate the
true 30-day rates depending on whether the presence of
follow-up is related to events or the lack thereof. Neverthe-
less, this discrepancy (2.2% vs 5.4% vs 7.1%) clearly supports
a more thorough 30-day analysis.
Finally, it is important to discuss the limitations of VR
and the analyses presented. The main weakness of these
results is the VR reliance on self-reporting with its biases
inherent to any registry-based study, as reported previou-
sly.8 Furthermore, some facilities participating in VR en-
tered either CAS or CEA data only; some institutions do
not perform CAS and elected to participate in the registry
and enter only CEA data, and others entered only CAS
data. In addition, although VR is designed for long-term
entry of follow-up, current CMS requirements for CAS
facility certification are limited to the initial hospitalization
and do not include follow-up. Thus, some facilities are not
motivated to enter follow-up information. However, the
concurrent entry of all patients treated for CAD in inde-
pendent and verifiable registries provides valuable informa-
tion about current clinical practice patterns.
CONCLUSION
Three major conclusions can be drawn from the analy-
ses of registry data. First, that event rates for carotid stent
treatment of ATH vs restenosis and radiation therapy pa-
tients are similar. This finding differs from results of prior
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 5 White et al 1123published reports. Next, symptomatic patients with ATH
etiology had statistically significant higher rates of death/
stroke/MI both periprocedurally and at 30 days compared
with the asymptomatic patients with atherosclerotic etiol-
ogy. And finally, consistent entry of patient data beyond
in-hospital (ie, intraprocedural and predischarge) event
rates, as currently mandated by CMS, is required to deter-
mine the true risks. This finding supports the importance of
continued data reporting in the postprocedure intervals to
enable accurate assessment of procedural success.
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